Navigation Links
Access MediQuip Moves Company Headquarters to Lake Mary, Florida
Date:11/9/2009

LAKE MARY, Fla., Nov. 9 /PRNewswire/ -- Access MediQuip, LLC, the nation's first and largest provider of outsourced implantable medical device management solutions to the healthcare industry, announced today that it is relocating its corporate headquarters to Lake Mary, Florida. The move, prompted by the firm's continued rapid growth, includes a major expansion of the Primera Blvd, Lake Mary office space that will open in January 2010 and relocation and expansion of the Houston facilities to the new, LEED® certified, One & Two Oak Park complex in the Westchase District.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090310/CG80801LOGO)

"Our growth is fueled by success in helping our clients reduce healthcare costs and improve patient care," said Access MediQuip Chief Executive Officer Tim Hargarten. "Access MediQuip is pleased to be able to continue supporting job growth and further economic development in the greater Orlando and Houston markets."

Access MediQuip was founded in 1997 to bring clarity and efficiency to the procurement, reimbursement and management of high-cost implantable medical devices such as orthopedic and spinal implants. Since that time, Access MediQuip has become the nation's leading provider of implantable medical device management solutions. The company has expanded its services to more than 2,500 healthcare payers and providers, and 175 device manufacturers to help manage implantable medical devices used for thousands of procedures. Access MediQuip has also developed the industry's largest database of claims information for implantable medical devices to provide payers, manufacturers and providers with the most comprehensive data available on U.S. implantable medical device costs and utilization rates.

"Our expanded Houston facilit
'/>"/>

SOURCE Access MediQuip, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
2. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
3. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
4. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
5. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
6. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
8. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
11. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Actavis plc (NYSE: ... Company has received a complete response letter from ... its New Drug Application (NDA) for the fixed-dose ... treatment of hypertension.   Photo - ... disappointed in the receipt of a complete response ...
(Date:12/24/2014)... 24, 2014 Soligenix, Inc. (OTCQB: SNGX) ... developing products that address unmet medical needs in ... today that on December 24, 2014 it closed ... The Company raised approximately $2.3 million in gross ... the net proceeds from the offering to fund ...
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, 2014 ... a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics ... medical need and commercial potential, today announced that ... 2,050,000 shares of its common stock and Series ... common stock.  Funds under the management of QVT ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4
(Date:12/25/2014)... December 26, 2014 The report ... to 2023” focuses on the current treatment landscape, ... the colorectal cancer market. Stivarga is a drug ... or rectal cancer. Boehringer Ingelheim is developing nintedanib ... treatment of refractory CRC in the US, Europe, ...
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 The ... to 2023” focuses on the current treatment landscape, unmet ... cancer market. TS-1 is an anti-cancer drug which is ... orally and is also used for treating gastric cancer ... and otastat potassium. The drug was first approved in ...
(Date:12/25/2014)... York, New York (PRWEB) December 25, 2014 ... the 2010 DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) ... LLP reports. According to an Order issued in the ... 20th, the Court will convene an open conference on ... Building and United States Courthouse in West Palm Beach, ...
(Date:12/25/2014)... months the trends for evening dresses shift and ... of the hottest styles in the next few months.” The ... 26 A-line sweetheart evening dresses, and announces the availability of ... trying our best to help a lady to show off ... prices, we provide discounted delivery costs to our customers worldwide. ...
(Date:12/25/2014)... Recently, iFitDress.com, the popular online supplier of wedding dresses and ... of black one-shoulder cocktail dresses . In addition, all ... at discounted prices, up to 70% off. , ... weeks only. You know, we have thousands of frequent callers ... new items can visit our website for more details. The ...
Breaking Medicine News(10 mins):Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2
... a motive of enabling women the best possible avenues to ... free breast cancer screening// in Dubai, scheduled to begin next ... in the emirate, UAE nationals, expatriates and visitors, to avail ... is absolutely essential to achieve better treatment outcomes. ...
... leaders in Wales are calling on the National Assembly for ... and release// patients from a heavy financial burden. ... people to park at hospitals is an indirect tax on ... hospital clinics do so by car. Often, these people have ...
... Anti-retrovirals have always been a blessing for the HIV patients, ... double blessing; ARV’s are capable of halting// the progress of ... is well known that HIV-infection could lead to mental illness. ... to HIV. Dr Michelle Rogers, a psychiatrist, says: "There were ...
... from Bristol University has developed a technique, using luciferase, to ... in detecting// damage to heart cells after a heart attack. ... for rapid recovery from cardiac arrests and heart surgery. This ... of Biological Chemistry. ,Dr Elinor Griffiths and her ...
... published the findings of the head to head trial of ... The study was an effort in drawing a methodical comparison ... ED and diabetes, hypertension, and/or hyperlipidemia. The results showed that ... use of this drug. ,A total of 1,057 ...
... records in paper form and scattered across the offices ... need those records// most--when you're lying on a gurney ... to do. Sometimes they do the wrong thing: in ... from medical mistakes, and 1.5 million people suffer from ...
Cached Medicine News:Health News:Abolish Car Parking Charges at Welsh Hospitals, says BMA Cymru Wales 2Health News:Abolish Car Parking Charges at Welsh Hospitals, says BMA Cymru Wales 3Health News:Abolish Car Parking Charges at Welsh Hospitals, says BMA Cymru Wales 4Health News:A glowing energy measure for heart cells 2Health News:Patients suffering ED happy with Vardenafil drugs 2Health News:Dying for Data 2
This model of bench top refrigerated incubator has been designed to suit the TPS-32 platelet shaker....
ELISA for detection of Anti-Gliadin IgG....
An enzyme-linked immuno-sorbent assay for the detection and quantitation of anti-tissue Transglutaminase in serum of patients with Celiac Disease and Dermatitis Herpetiformis....
Enzyme immunoassay for the quantitative determination of Gliadin-IgG antibodies in serum and plasma. This kit provides specific determination of gliadin antibodies by using highly purified gliadin....
Medicine Products: